Recent progress on sanofi pasteur's dengue vaccine candidate

Journal of Clinical Virology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Lang, Jean ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Flavivirus immunity; Reactogenicity; Seroconversion; Tetravalent vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; PLACEBO; TETRAVALENT DENGUE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DENGUE; HUMAN; PRIORITY JOURNAL; SEROCONVERSION; THAILAND; VIREMIA; VIRUS IMMUNITY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DENGUE VACCINES; HUMANS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 70349576213     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70291-4     Document Type: Article

References (14)

1. Sabchareon A., Lang J., Chanthavanich P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 (2002) 264-272
2. Sabchareon A., Lang J., Chanthavanich P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 (2004) 99-109
3. Kitchener S., Nissen M., Nasveld P., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24 (2006) 1238-1241
4. Kanesa-thasan N., Sun W., Kim-Ahn G., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19 (2001) 3179-3188
5. Arroyo J., Guirakhoo F., Fenner S., et al. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75 (2001) 934-942
6. Guirakhoo F., Zhang Z.X., Chambers T.J., et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257 (1999) 363-372
7. Guirakhoo F., Pugachev K., Zhang Z., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78 (2004) 4761-4775
8. Brandler S., Brown N., Ermak T.H., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72 (2005) 74-81
9. McGee C.E., Lewis M.G., Claire M.S., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 197 (2008) 693-697
10. McGee C.E., Tsetsarkin K., Vanlandingham D.L., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVaxdengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 197 (2008) 686-692
11. Guy B., Guirakhoo F., Watson M., et al. Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]. Vaccine 26 (2008) 4107-4108
12. Edelman R., and Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: Summary of a World Health Organization Technical Consultation. Vaccine 26 (2008) 4113-4119
13. Timiryasova TM, Brechet D, Dapkiewicz R, et al. Development of a Dengue ELISA-based micro-neutralisation assay. Abstract 807. 55th Annual Meeting American Society of Tropical Medicine and Hygiene. 2006.
14. Morrison D, Rosario Capeding M, Poo J, et al. Safety and infectivity of tetrava- lent chimeric live attenuated dengue vaccine in different age populations in endemic and non-endemic areas. Abstract no 344. 56th Annual Meeting American Society of Tropical Medicine and Hygiene. 2007